Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK Gets New Start For Breo With FDA Approval In Asthma

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approved Breo Ellipta as a once-daily treatment for asthma, a new indication for a drug that has been on the market since October 2013 for COPD.

You may also be interested in...

Breo Ellipta Stumbles On Pediatric Asthma Claim, But Advair Helps Break The Fall

FDA approves GlaxoSmithKline’s LABA/inhaled corticosteroid combo for asthma in adults but says more data needed in adolescents. GSK plans to throw additional promotional support behind the existing pediatric asthma claim for Advair, which is expected to face generic competition in the coming years.

GSK Lays Out Five-Year Growth Strategy, Underpinned By Advair Generics

The company’s five-year forecast includes the entry of Advair generics for the first time, but CEO Andrew Witty says pharma sales will nonetheless grow at low single-digits from 2016 to 2020.

Keeping Track: Kybella, Ixinity, Raplixa Approved; Three 'Complete Responses' Surprise No One

The latest drug development news and highlights from our FDA Performance Tracker.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts